<DOC>
	<DOCNO>NCT00171184</DOCNO>
	<brief_summary>The objective study ass efficacy , safety tolerability 12-weeks treatment darifenacin patient age &gt; Ý 65 year OAB .</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability Darifenacin Patients Aged &gt; 65 Years With Overactive Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Darifenacin</mesh_term>
	<criteria>Symptoms OAB least six month prior Visit 3 Symptoms OAB 7 day diary period immediately precede Visit 3 : ≥ 1 UUIE average per day ≥ 10 episode micturition average per day A total daily urinary volume &gt; 3000 ml mean volume void per micturition &gt; 300 ml verify micturition diary randomization Postvoid residual ( PVR ) urinary volume &gt; 100 ml Clinically significant stress urinary incontinence determine investigator Clinically significant bladder outlet obstruction determine investigator Concomitant diseases use anticholinergic drug contraindicate , e.g . urinary retention , gastric retention , uncontrolled narrowangle glaucoma , myasthenia gravis , severe hepatic impairment ( Child Pugh B C ) , severe ulcerative colitis , toxic megacolon . Other protocol inclusion / exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Overactive bladder , Darifenacin , M3 muscarinic receptor antagonist , elderly population</keyword>
</DOC>